LearnGlossaryMarketStocksSuperinvestorsSign in

BCRX

BioCryst Pharmaceuticals, Inc.

Healthcare · $2.2B market cap

Verdict

We can't put a fair value on BCRX right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-11.2% a year✗
Sales growth16.6% a year✓
Free cash flow growth-12.1% a year✗
Return on invested capital-20.7%✗

Follow BCRX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Aug 31, 2026: no open-market purchases and 5 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Frank Steven

director · 2026-08-31

Award

$12K

McKee Amy E

director · 2026-08-31

Award

$6K

MILANO VINCENT

director · 2026-08-31

Award

$11K

Milne Jill C.

director · 2026-08-31

Award

$12K

Stonehouse Jon P

director · 2026-08-31

Award

$6K

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works